Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 534,843
  • Shares Outstanding, K 163,062
  • Annual Sales, $ 63,550 K
  • Annual Income, $ -6,520 K
  • 60-Month Beta 0.82
  • Price/Sales 8.44
  • Price/Cash Flow N/A
  • Price/Book 12.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.02
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.04
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.18 +5.66%
on 10/10/19
3.79 -11.35%
on 09/19/19
-0.23 (-6.41%)
since 09/13/19
3-Month
2.90 +15.86%
on 07/17/19
3.79 -11.35%
on 09/19/19
+0.32 (+10.53%)
since 07/15/19
52-Week
2.53 +32.81%
on 12/28/18
3.96 -15.15%
on 03/04/19
+0.03 (+0.90%)
since 10/15/18

Most Recent Stories

More News
Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September...

ATRS : 3.36 (+2.44%)
Teva Announces Availability of a Generic Equivalent of EpiPen Jr(R) (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr(R)(1) (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S....

TEVA : 6.97 (+3.57%)
ATRS : 3.36 (+2.44%)
Antares Pharma: 2Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported a loss of $2.2 million in its second quarter.

ATRS : 3.36 (+2.44%)
Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue

ATRS : 3.36 (+2.44%)
Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Management...

ATRS : 3.36 (+2.44%)
Needle Free Drug Delivery Devices Market is expanding steadily at a CAGR of 9.90% till 2023, Noted TMR

Healthcare industry across the globe is booming due to increasing importance on saving life and ensuring every person to get adequate healthcare facilities. Governments are also taking significant and...

ATRS : 3.36 (+2.44%)
ZGNX : 42.47 (+2.41%)
Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares" or "the Company") today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC),...

ATRS : 3.36 (+2.44%)
HTGC : 13.40 (+0.07%)
Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday...

ATRS : 3.36 (+2.44%)
Antares Pharma: 1Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Thursday reported a loss of $5.5 million in its first quarter.

ATRS : 3.36 (+2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATRS with:

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

2nd Resistance Point 3.46
1st Resistance Point 3.41
Last Price 3.36
1st Support Level 3.29
2nd Support Level 3.22

See More

52-Week High 3.96
Fibonacci 61.8% 3.41
Last Price 3.36
Fibonacci 50% 3.24
Fibonacci 38.2% 3.08
52-Week Low 2.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar